Staar Surgical Company STAA

$21.67 -0.71 (-3.17%)

Valuation

Market cap
1,122,223,000
Revenue TTM
$239,440,000
Net income TTM
$-80,450,000
PE ratio
34.94
Forward PE
57.33
Profit margin
-33.60%
Debt to equity
0.00

Trading

Volume
592,400
Avg volume
995,508
Day's range
$21.44 – $22.52
Shares out
50,144,000
Stochastic %K
15%
Beta
1.17
Analysts
Sell
Price target
$28.22

Price

Company profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, h...

Show more

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
626 303 7902
Website
https://www.staar.com
Address
25510 Commercentre Drive, Lake Forest, United States

Latest news

Stocktwits

Bogwood Oct 9, 1:14 AM
$STAA Neal continues to communicate to us in code. Today's BD appointment from JNJ was to foreshadow the acquieree. The $50M repurchase authorization foreshadows the buyout price of $50, and David Bailey rejoining implies it will be sooner than later
0 replies
prismmarketview Oct 8, 7:28 PM
On #WorldSightDay, more than a billion people still lack the eye care they need. This year’s call to #LoveYourEyes puts the focus on making care accessible, available and affordable for everyone. Five public companies are helping move that mission forward. Sight Sciences ($SGHT) is expanding treatment options for glaucoma and dry eye through procedure-based care, including its implant-free OMNI surgical system. STAAR Surgical ($STAA) offers implantable lenses that give patients an alternative to glasses, contacts and laser vision correction. Opus Genetics ($IRD) is developing gene therapies for rare inherited retinal diseases, including a form of childhood blindness. Annexon ($ANNX) is advancing a potential treatment to preserve vision in people living with geographic atrophy. From expanding access to developing new treatments, these companies reflect different approaches to a shared goal: helping more people see a brighter future. #LoveYourEyes #EyeHealth #HealthcareInnovation
1 replies
alphadog10 Oct 1, 6:54 PM
$LCTX Self dealing is broadwood and companies middle name. Now imagine watching $STAA go to $163 then throwing a temper tantrum all the way down at $30 crying undervalued and begging for at least $50 while ousting CEO and Directors. Thats some legacy !
0 replies
topstockalerts Sep 30, 12:19 AM
Stifel upgraded STAAR Surgical from Hold to Buy and raised its price target to $31 from $28, citing an attractive entry point and potential for sustained, profitable double-digit revenue growth. Analyst Thomas Stephan expects a favorable product mix shift toward the higher-priced EVO+ implantable collamer lens in China, combined with easier year-over-year comparisons outside China, to drive a meaningful sales inflection in the second half of 2026. Stifel’s scenario analysis projects an 11% compound annual growth rate in sales from 2026 to 2028, above the roughly 8% consensus estimate. The upgrade also follows STAAR’s authorization of a $50 million share-repurchase program, funded by free cash flow and available cash, which management said reflects confidence in the company’s financial strength and view that the shares are undervalued. The company’s exposure to a recovering refractive market in China also supports the thesis. $STAA
0 replies
anachartanalyst Sep 29, 11:01 AM
$STAA https://anachart.com/wp-content/uploads/2026/09/1790679673_soc-img.jpg
0 replies
StockBraker Sep 26, 11:01 AM
$STAA US-China trade issues and tariffs are actively affecting STAAR Surgical’s gross margins and stock performance, even though its underlying product sales in China remain exceptionally strong. The company's recent earnings report showed that quarterly sales in China rose more than 100% to $52.3 million, but macro headwinds prevent full valuation expansion. Broadwood argued Alcon’s buyout severely undervalued STAAR, targeting a standalone value of $50 per share. If STAAR Surgical fully executes its $50 million buyback at a fixed price of $20 per share, it will remove 2.5M shares from the open market. https://www.fool.com/investing/2026/09/25/why-staar-surgical-stock-soared-today/
1 replies
prismmarketview Sep 25, 4:41 PM
$STAA STAAR Surgical’s board approves $50M share repurchase authorization, expected to run ~12 months (board can extend/shorten). Funded via organic free cash flow + existing cash, no new debt. As of July 3: $181.5M cash/cash equivalents/AFS investments, zero outstanding debt. ~50.1M shares outstanding as of Aug 7. CEO Warren Foust cites confidence from recent revenue growth, profit expansion, and innovation (EVO ICL franchise); calls shares "substantially undervalued." CFO frames it as balanced capital allocation. Reminder: authorization ≠ commitment, actual repurchase amount/timing/pricing depends on market conditions and management decisions going forward. $STAA #MedTech #Buyback https://prismmarketview.com/staar-surgical-authorizes-50-million-stock-buyback-citing-cash-position-and-business-progress/
0 replies
prismmarketview Sep 25, 4:31 PM
We’re adding STAAR Surgical $STAA to the PRISM MedTech Index. https://prismmarketview.com/index/medtech/ STAAR has spent more than 30 years developing implantable lenses for vision correction, with more than 4 million Implantable Collamer® Lenses sold across 85+ countries. Its EVO ICL™ provides an alternative to laser vision correction without removing corneal tissue or the eye’s natural crystalline lens. Recent company research points to a changing refractive surgery market. STAAR reported that U.S. laser procedure volumes have declined 52% since 2022 while EVO ICL adoption increased 76% over the same period. Its global study surveyed 7,800 consumers across seven markets. The company also just authorized a $50 million share repurchase program, to be funded with cash on hand and free cash flow. As of July 3, STAAR reported $181.5 million in cash, cash equivalents and investments and no outstanding debt. https://prismmarketview.com/companies/staar-surgical-company/#about
0 replies